Eli Lilly stock rises as FDA gives ‘Breakthrough’ tag to ovarian cancer drug, earnings date set
Eli Lilly’s stock jumped 3.6% on Wednesday, finishing at $1,078.52. The boost came after the company announced that the U.S. Food and Drug Administration awarded Breakthrough Therapy designation to its experimental ovarian cancer drug.
